AIM ImmunoTech Inc

AIM ImmunoTech Inc is a clinical-stage biopharmaceutical company focused on developing treatments for immune disorders, viral diseases, and cancers. Its primary aim is to develop and commercialise innovative drugs to enhance the immune system's function against various diseases. The company has a global reach. Operating within the biotechnology sector, AIM ImmunoTech Inc specifically focuses on therapies like Ampligen (rintatolimod), an experimental drug which is currently being used to treat pancreatic cancer patients in an Early Access Program (EAP). The company's approach is centred on modulating the immune system to help patients combat complex conditions and potentially improve health outcomes. Diversify your virtual portfolio by following AIM shares on eToro. This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.